Head- to head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard.
18F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)-based radiopharmaceutical for imaging prostate cancer. The aim of this study is to compare the diagnostic accuracy of 18F-PSMA-1007 with 68Ga-PSMA-11 PET/CT in the same patients presenting with newly diagnosed intermediate and high-risk prostate cancer. Methods: Sixteen patients with intermediate and high-risk PCa underwent 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CTs within 15 days. PET findings were compared between the two radiotracers and to reference-standard pathological specimens obtained from radical prostatectomy. Cohen's kappa coefficient was used to assess the concordance between 18F-PSMA-1007 and 68Ga-PSMA-11 for detection of intra-prostatic lesions. McNemar's test was used to assess agreement between intra-prostatic PET/CT findings and histopathological findings. Sensitivity, specificity, positive predictive value and negative predictive value were reported for each radiotracer. SUVmax was measured for all lesions and tumor-to-background activity was calculated. Areas under receiver operating characteristic curves were calculated for discriminating diseased vs. non-diseased prostate segments and optimal SUV-cutoff values were calculated using the Youden's index for each radiotracer. Results: PSMA-avid lesions in the prostate were identified in all 16 patients with an almost-perfect concordance between the two tracers (kappa ranged from 0.871 to 1). Aside from the dominant intra-prostatic lesion, similarly detected by both radiotracers, a second less intense positive focus was detected in 4 patients only with 18F-PSMA-1007. Three of these secondary foci were confirmed as Gleason grade 3 lesions whereas the fourth was shown on pathology to represent chronic prostatitis. Conclusion: This pilot study shows that both 18F-PSMA-1007 and 68Ga-PSMA-11 identify all dominant prostatic lesions in patients with intermediate and high-risk prostate cancer at staging. 18F-PSMA-1007 however may detect additional low-grade lesions of limited clinical relevance.